Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Pre-filled Pen 1,3 |
|
Dosage
The standard dosage is usually one subcutaneous injection daily, in the thigh or lower abdomen. Please refer to the license holder for further details.
Indications
Treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Teriparatide increases BMD reduces the risk of vertebral and nonvertebral fractures.
Indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.
Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.
Contra-Indications
Hypersensitivity to active substance or any other excipients.
Pregnancy, lactation.
Patients with Paget’s disease, hypercalcemia, metabolic bone disease, bone tumors.
Patients that had underwent radiation therapy for the bones.
Severe renal impairment
Children or a young patient in the growing stage.
Hyperparathyroidism.
